ASCO: Two-Year Survival Seen with Sutent in Kidney Cancer
0 Views
administrator
07/10/23
http://www.medpagetoday.com
Robert A. Figlin, M.D., City of Hope, Duarte, Calif.
CHICAGO -- In patients with treatment-naive advanced renal cell carcinoma, treatment with sunitinib (Sutent) more than doubled progression-free survival compared with interferon alfa.
Medpage Today: http://medpagetoday.com
Online CME - Continuing medical education: http://www.medpagetoday.com/cme/
Latest medical news: http://www.medpagetoday.com/latest/
The MedPage Today app:
iOS: https://goo.gl/JKrkHq
Android: https://play.google.com/store/....apps/details?id=com.
MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageToday
Medpage Today on Facebook: https://www.facebook.com/MedPageToday
-
Category
Show more
Facebook Comments
No comments found